Search clinical trials for: Rebif® New Formulation

Total 275 results

EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
EMD Serono

Completed

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, Sweden
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Derming SRL

Completed

Evaluation of Tolerance and Trichological Efficacy of a Food Supplement

Telogen Effluvium
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.

Substance Dependence

United Kingdom
The Netherlands Cancer Institute

Completed

Study With Improved Solubility Pazopanib

Pharmacokinetics of Pazopanib

Netherlands
Eli Lilly and Company

Completed

A Study of LY3039478 in Healthy Participants

Healthy

United States
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Merck KGaA, Darmstadt, Germany

Completed

Transition to Rebif New Formulation (TRANSFER)

Relapsing Multiple Sclerosis

France, Germany
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Takeda

Completed

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Healthy
GlaxoSmithKline

Completed

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Herpes Labialis

Japan
ESM Technologies, LLC

Completed

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

Osteoarthritis | Fibromyalgia

United States
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Takeda

Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Hypothyroidism

Belgium
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

HIV Infections
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Embera NeuroTherapeutics, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Cocaine Use Disorder

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
TaiGen Biotechnology Co., Ltd.

Completed

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Healthy

United States
Merck KGaA, Darmstadt, Germany

Completed

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device (RebiQoL)

Multiple Sclerosis | Relapsing-Remitting

Sweden, Germany
EMD Serono

Completed

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (REPLAY)

Multiple Sclerosis

Italy, Russian Federation, United States, Argentina, Venezuela, Canada, Tunisia, France
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
Allergan

Completed

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Dry Eye Disease (DED)

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Bavarian Nordic

Completed

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Smallpox

United States
Merck KGaA, Darmstadt, Germany
EMD Serono Canada Inc.

Completed

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome (CIS-ON)

Clinically Isolated Syndrome

Canada
Boehringer Ingelheim

Recruiting

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Korea, Republic of, Israel, Spain, Australia, Japan, Italy, Germany, Denmark, Belgium, Lithuania, China, Canada, Malaysia, Singapore, New Zealand, France, Mexico, Netherlands, Greece, United Kingdom, Bulgaria, Philipp... and more
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
EMD Serono
Merck Serono International SA

Completed

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Multiple Sclerosis, Relapsing-remitting
Waukesha Memorial Hospital
The Cleveland Clinic

Completed

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Relapsing-Remitting Multiple Sclerosis

United States
GlaxoSmithKline

Completed

Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants

Hypertension, Pulmonary

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
AbbVie (prior sponsor, Abbott)

Completed

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
Allergan

Completed

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Bilateral LASIK Surgery

Australia, Canada
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Measles | Rubella | Mumps | Varicella

Taiwan, Singapore
Bayer

Completed

Moisturizing Effect of Two Dexpanthenol Formulations

Skin Abnormalities

France
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Bayer

Completed

Efficacy of Dexpanthenol in Thermic Erythema

Erythema

France

3

Subscribe